LegoChem Bioscience, Inc.A Leading Chemistry-Based Venture Company<br />COMPANY<br />OVERVIEW<br />
Contents<br />Company Overview<br />Business Approach<br />Project Overview<br />Summary<br />
Mission Statement<br />ABOUT<br />ABOUT          BUSINESS          PROJECT          SUMMARY<br />LegoChem Biosciences ( “L...
Corporate Overview<br />Established in May 2006  (Daeduk Science Town, Daejeon, Korea )<br />Raised 10.3 billion Korean wo...
Management Team<br />ABOUT<br />ABOUT          BUSINESS          PROJECT          SUMMARY<br /> Yong Zu Kim, Ph.D<br />Tae...
Business Strategy and Model<br />BUSINESS<br />ABOUT          BUSINESS          PROJECT          SUMMARY<br />Model 1 : In...
BUSINESS<br />ABOUT          BUSINESS          PROJECT          SUMMARY<br />Proprietary Drug Development<br />(chemistry ...
◆Early stage L/O</li></ul>Core Technology<br /><ul><li>Medicinal Chemistry
LegoChemistry
Screening
Early ADMET</li></ul>Drug development through collaborative research<br />(Biology-driven challenge)<br /><ul><li>◆Drug di...
◆Early~mid stage L/O</li></ul>Business Research Service<br /><ul><li>◆Customized compound synthesis
◆ Early ADME/T service</li></ul>Gate Decision System<br />Business Model<br />
Preclinical Candidate<br />Confirmation<br />Pre-Candidate<br />Confirmation<br />Phase I Candidate<br />Confirmation<br /...
Selectivity
Metabolic stability
CYP inhibition  (DDI)
Upcoming SlideShare
Loading in …5
×

Legochem Company ppt

1,966 views

Published on

Published in: Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,966
On SlideShare
0
From Embeds
0
Number of Embeds
24
Actions
Shares
0
Downloads
38
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Legochem Company ppt

  1. 1. LegoChem Bioscience, Inc.A Leading Chemistry-Based Venture Company<br />COMPANY<br />OVERVIEW<br />
  2. 2. Contents<br />Company Overview<br />Business Approach<br />Project Overview<br />Summary<br />
  3. 3. Mission Statement<br />ABOUT<br />ABOUT BUSINESS PROJECT SUMMARY<br />LegoChem Biosciences ( “LCB”) is committed to the discovery and development of novel small-molecule drugs employing faster and more efficient ways by combining LegoChemistry and early ADME/T screening platform technologies. <br />
  4. 4. Corporate Overview<br />Established in May 2006 (Daeduk Science Town, Daejeon, Korea )<br />Raised 10.3 billion Korean wons (≈ 10 million US$) since its inception<br />Has built sustainable pipelines in the therapeutic areas of antibiotics, anticoagulants, and oncology<br />The frontrunner, 2nd generation oxazolidinone antibiotics against MRSA is now in regulatory preclinical studies<br />CRO: MPI in USA<br />Novel FXa Inhibitor (anticoagulants) is in regulatory preclinical studies jointly with Green Cross, and is licensed out at the candidate stage to Green Cross in June 2009<br /> Experienced and seasoned executive and scientific management team<br /> Preparing IPO to KOSDAQ<br />ABOUT<br />ABOUT BUSINESS PROJECT SUMMARY<br />
  5. 5. Management Team<br />ABOUT<br />ABOUT BUSINESS PROJECT SUMMARY<br /> Yong Zu Kim, Ph.D<br />Tae Kyo Park, Ph.D<br />Sung Ho Woo, Ph.D<br />Sejin Park<br />Young Lag Cho, Ph.D<br />Ho Young Song, Ph.D<br />HyangSuk Lee<br />Chemistry <br />Sr. Director<br />Project Leader at LGLS 18 journal, 5 patent publications Ph.D. / Chemistry, Yonsei U.<br />CFO / VP<br />GM, R&D Management, 20 yrs at LGLS Co-Founder of LCB, BS/Economy, Korea Univ<br />CEO & President<br />Director of New Drug R&D , 23 yrs at LGLS Co-Founder of LCB, Ph.D. /Chemistry, KAIST<br />Head of Biology / VP<br />Project Leader, 5 yrs at LGLS Co-Founder of LCB, Ph.D. / Microbio, Ohio state <br />CTO & <br />Sr. VP<br />Project Leader, 10 yrs at LGLS Co-Founder of LCB, Ph.D. /Chemistry, MIT<br />Chemistry Director<br />Principal Research at LGLS, Ph.D. / Seoul Nation U. 8 journal, 2 patent publications<br />Biology Director<br />Research Scientist, 11 yrs at LGLS, 4 journal, 10 patent pub. MS /Biochem, Yonsei U.<br />
  6. 6. Business Strategy and Model<br />BUSINESS<br />ABOUT BUSINESS PROJECT SUMMARY<br />Model 1 : Independent R&D<br />Internal research & development up to phase 2a<br />License-out at early ~ mid stage (i.e. Oxazolidinone antibiotics, FXa Inhibitor)<br />Model 2 : Collaborative R&D<br />Joint research with strong biology platform up to phase IIa<br />License-out at early ~ mid stage (i.e. Anticancer : HSP90, Mitochondriotropic)<br />Model 3 : Sponsored R&D<br />Sponsored R&D cost from partner up to candidate stage<br />License-out to partner at candidate stage and developed & commercialized by partner (i.e. FVIIa Inhibitor)<br />RISK<br />CORE COMPETENCY<br />Biology Based<br />Med Chem Based<br />
  7. 7. BUSINESS<br />ABOUT BUSINESS PROJECT SUMMARY<br />Proprietary Drug Development<br />(chemistry –driven challenge)<br />Strategic Alliances<br /><ul><li>◆ Proprietary drug discovery candidates
  8. 8. ◆Early stage L/O</li></ul>Core Technology<br /><ul><li>Medicinal Chemistry
  9. 9. LegoChemistry
  10. 10. Screening
  11. 11. Early ADMET</li></ul>Drug development through collaborative research<br />(Biology-driven challenge)<br /><ul><li>◆Drug discovery and development of candidate
  12. 12. ◆Early~mid stage L/O</li></ul>Business Research Service<br /><ul><li>◆Customized compound synthesis
  13. 13. ◆ Early ADME/T service</li></ul>Gate Decision System<br />Business Model<br />
  14. 14. Preclinical Candidate<br />Confirmation<br />Pre-Candidate<br />Confirmation<br />Phase I Candidate<br />Confirmation<br />BUSINESS<br />ABOUT BUSINESS PROJECT SUMMARY<br />Establish 3 level gate systems for preclinical candidates, and define the evaluation criteria based on experience and know-how, to pre-validate and apply failing factors during the post preclinical development phase<br />Lead<br />3rd Gate<br />2nd Gate<br />1st Gate<br />Efficacy Focus<br /><ul><li>In vitro/in vivo efficacy
  15. 15. Selectivity
  16. 16. Metabolic stability
  17. 17. CYP inhibition (DDI)
  18. 18. Protein Binding
  19. 19. Solubility
  20. 20. Stability(plasma, solution)</li></ul>Safety Focus<br /><ul><li>Ames
  21. 21. hERG (Patch Clamp)
  22. 22. Single dose Tox
  23. 23. Repeated dose Tox(1W)</li></ul>PK/PD Focus<br /><ul><li>In vitro/in vivo efficacy
  24. 24. Selectivity
  25. 25. Metabolic stability
  26. 26. CYP inhibition (DDI)
  27. 27. Protein Binding
  28. 28. Solubility
  29. 29. Stability (plasma, solution)
  30. 30. PK (t1/2, Vd, CL, AUC)
  31. 31. Cytotoxicity
  32. 32. BA(rat) > 20%</li></ul>Gate Decision System<br />
  33. 33. Platform Technology: LegoChemistry<br />BUSINESS<br />ABOUT BUSINESS PROJECT SUMMARY<br />“New Lego block” molded into existing best chemical structures<br />New Pieces of Lego Block<br />Way of Implementation<br />AREA<br />Disease area with experience<br />Validated (existing) target<br />METHOD<br />Fragment-based approach<br />Multi-component reactions<br />Replacement of existing subgroup<br />Previously unknown<br />Known but not well-explored<br />LCB has more than 20 drug-like unique scaffolds<br />Derived from same Lego Block<br />Successful cases<br />FXa inhibitor (LCB02-0133)<br />Antibiotics (LCB01-0371)<br />C<br />A<br />B<br />Time to candidate : 12 ~ 18 months<br />
  34. 34. BUSINESS<br />ABOUT BUSINESS PROJECT SUMMARY<br />Shortening candidate discovery time from 5 to 3 years by utilizing tools like LegoChemistry<br />기존 Approach<br />레고켐 Approach<br />Present<br />1990<br />LegoChemistry / Affi. assay<br />Combi-Chem/HTS<br />Traditional approach<br />(one by one)<br />(multi by semi-multi)<br />(once and all)<br /><ul><li>LegoChemistry</li></ul> - Synthesis of various materials simultaneously without separation<br /> - Starts from Druglike scaffold<br /><ul><li>Affinity Assay</li></ul> - One conclusive assay for complete mixture of synthetic material<br /><ul><li>Combi-Chem</li></ul> - Simultaneous synthesis of various substances / Individual Separation<br /> - druglikelack of verification<br /><ul><li> HTS</li></ul>- Fixed unit multi-well Assay<br />Candidate Discovery Method<br /><ul><li> Manual single synthesis
  35. 35. Singleton Assay
  36. 36. 3,800 : 1
  37. 37. Over 5 years
  38. 38. 5,800 : 1
  39. 39. Average 5 years
  40. 40. 500 : 1 (or less)
  41. 41. Less than 3 years</li></ul>R&D<br />Productivity<br />(Candidate for discovery)<br />☞ Merck Standard<br />The synthesis of core competencies<br />
  42. 42. BUSINESS<br />ABOUT BUSINESS PROJECT SUMMARY<br />More than 5 clinical pipelines for new drug by 2012<br />(Benchmarking: Gilead Science)<br />Initiate pipeline<br />(’06 ~’08)<br />Grow pipeline<br />(’09 ~’11)<br />Sustain pipeline <br />(’12 ~ )<br />2 Preclinical candidates,<br />1 License-out<br />1 Co-Research contract<br />3 Clinical pipeline<br />2 License-out<br />1 preclinical study/year<br />5 Clinical pipeline<br />3 License-out<br />1 clinical study / year<br />Output<br />Collaboration network<br />Global network<br />Global licensing-out<br />Independent research and development company<br />Manage the process from discovery to development<br />Core<br />Competencies<br />Mid-term Business Plan<br />
  43. 43. Research Projects<br />PROJECT<br />ABOUT BUSINESS PROJECT SUMMARY<br />Project Selection Guideline<br />Management’s Previous Experience<br />antibiotics, anticoagulants, anticancer<br />Attractiveness to big pharm<br />unmet medical needs<br />Portfolio Balance (risk management)<br />best-in-class vs. first-in-class<br />Projects<br />Antibiotics<br />Oxazolidinone antibiotics , MDR-TB<br />Gram(-) antibiotics<br />Anticoagulants <br />FXa inhibitor (Partnered with Green Cross)<br />FVIIa inhibitor (Partnered with Hanmi)<br />FXIa inhibitor <br />Anti-cancer <br />HSP 90 (Partnered with BoramPharma)<br />Mitochondriotropic<br />Others<br />DDR2 / HIF-1(Wondonin) / CD-99 <br />
  44. 44. Project Roadmap<br />PROJECT<br />ABOUT BUSINESS PROJECT SUMMARY<br />(by Green Cross)<br />
  45. 45. Discovery Projects: Summary<br />PROJECT<br />ABOUT BUSINESS PROJECT SUMMARY<br />
  46. 46. Scope of IP landscape<br />ABOUT BUSINESS PROJECT SUMMARY<br />SUMMARY<br />FXa inhibitors<br />FVIIa inhibitors<br />Anticancer<br />Patent to be published<br />+<br />Antibiotics<br />
  47. 47. Summary of LCB <br />ABOUT BUSINESS PROJECT SUMMARY<br />SUMMARY<br />Experienced and skilled researchers<br />Hands on experience on driving project from early lead discovery to FDA approval <br />Established experience and network for licensing-out, collaboration, and negotiation with multi-national pharmaceutical companies<br />Excellence of Core Technology<br />Unique distinction of LegoChemistry scaffold approach<br />Ability to generate consistent project pipeline ( >20 novel Scaffold, 25,000 compounds focused library) <br />Systematic research plan via Gate Decision System<br />Established guidelines for key stage decision to distinguish between ‘good’ and ‘bad’ drugs<br />Implementing ‘fast track’ new drug discovery<br />Passion for new drug development<br />New drug discovery is the only way to survive!<br />“Establishing a new drug pipeline is dependent on securing drug-like leads, and LCB has the necessary technology, system and passion to deliver it.”<br />
  48. 48. Contact<br />LegoChem Biosciences, Inc.<br />Daejeon Bio Venture Town, 461-8 Jeonmin-dong, Yuseong-gu, Daejeon, 305-811, South Korea<br />http://www.legochembio.com/<br />CONTACT: Sung-Ho Woo, Ph.D. Biology Director & Senior VP <br />[Tel] +82-42-861-0688 <br />[Fax] +82-42-861-0689 <br />E-mail: sungwoo@legochembio.com<br />Request for more materials<br />ONE PAGE: Brief outline of a project in a one page PDF file<br />PROJECT PPT: Detailed version of a project description and a 5 MIN VIDEO presentation<br />COMPANY DOC: Comprehensive overview of company’s business plan and project description in written format.<br />

×